Find out more about A.I.den - our SearchBot

B Cells antibody | FMC7

100% Secure
Anti Human B Cells Antibody, clone FMC7 gallery image 1
Staining of human peripheral blood lymphocytes with FITC conjugated Mouse anti Human B-Cells antibody, clone FMC7 (MCA792F).

Mouse anti Human B Cells:FITC

Product Type
Monoclonal Antibody
Clone
FMC7
Isotype
IgM
Product Code Applications Pack Size List Price Quantity
MCA792F
Datasheet
F
MSDS
100 Tests/1ml loader

Mouse anti Human B cells antibody, clone FMC7 recognizes a glycoprotein antigen of ~105 kDa expressed by B lymphocytes. The FMC7 antigen is expressed by peripheral B lymphocytes, and has been used widely in the study of B cell malignancy. Mouse anti Human B cells antibody, clone FMC7 has been used extensively to differentiate various types of B cell malignancy. B-CLL is generally considered to be negative for FMC7 expression, but strong staining is seen in many other types of B cell lymphoma, including prolymphocytic leukemia and hairy cell leukemia.

The nature of the FMC7 antigen has remained poorly defined following its first description in 1981. The expression pattern closely corresponds to that seen with CD22, but studies have shown that FMC7 does not recognize the CD22 molecule itself. Mouse anti Human B cells antibody, clone FMC7 recognizes a conformational epitope on the CD20 molecule, most likely a multimeric complex of CD20 (Serke et al. 2001). Identity of CD20 as the antigen recognized by Mouse anti Human B cells antibody, clone FMC7 was further confirmed by strong recognition of recombinant CD20 expressed in hematopoietic and non-haematopoietic cell lines and abolition of binding in CD20 extracellular domain mutations. The recognized epitope has also been shown to be cholesterol dependent (Polyak et al. 2003).

Product Details

Target Species
Human
Product Form
Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Preparation
Purified IgM prepared by gel filtration
Buffer Solution
TRIS buffered glycine
Preservative Stabilisers
0.1% Sodium Azide (NaN3)
0.2% Bovine Serum Albumin
Immunogen
HRIK cells - Human B-Lymphoblastoid line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee
18 months from date of despatch.

More Information

UniProt
P11836
Entrez Gene
MS4A1
GO Terms
GO:0005887 integral to plasma membrane
GO:0006955 immune response
GO:0042113 B cell activation
Regulatory
For research purposes only

Applications of B Cells antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)

Negative Isotype Controls Available

Description Product Code Applications Pack Size List Price Quantity
Mouse IgM Negative Control:FITC MCA692F F 0.1 mg loader

Useful Reagents Available

Description Product Code Applications Pack Size List Price Quantity
Human Seroblock BUF070A F 50 Test
Human Seroblock BUF070B F 200 Test

Product Specific References

Source Reference

  1. Brooks, D.A. et al. (1981) Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes.
    J Immunol. 126 (4): 1373-7.

References for B Cells antibody

  1. Catovsky, D. et al. (1981) Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.
    Blood. 58 (2): 406-8.
  2. Serke, S. et al. (2001) Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after Rituxan therapy and transfectant cell analyses.
    Cytometry (Comm. Clin. Cytometry) 46:98-104
  3. Zola H., et al. (1984) The human B cell lineage studied with monoclonal antibodies.
    In Leucocyte Typing Ed.A. Bernard, Springer Verlag. p363-71.
  4. Zola, H. et al. (1984) The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression.
    J Immunol. 133 (1): 321-6.
  5. Bloem, A.C. et al. (1988) Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7.
    J Immunol. 140 (3): 768-73.
  6. Zola, H. et al. (1987) Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules.
    Dis Markers. 5 (4): 227-35.
  7. Ghia, P. et al. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
    Blood. 101 (4): 1262-9.
  8. Ferro LM & Zola H (1990) Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro.
    Immunology. 69 (3): 373-8.
  9. Collins R.J., et al. (1992) Malignant lymphoma: reactive with the monoclonal antibody FMC7.
    Pathology 15: 350.
  10. Zucchetto A et al. (2006) A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
    J Cell Physiol. 207 (2): 354-63.
  11. Wang, C. et al. (2002) Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL.
    Leuk Res. 26 (12): 1125-9.
  12. Amato, D. et al. (2007) Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.
    Am J Clin Pathol. 128 (2): 333-8.
  13. Polyak, M.J. et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.
    Leukemia. 17 (7): 1384-9.
  14. Domingo-Domènech, E. et al. (2002) CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
    Haematologica. 87 (10): 1021-7.
  15. Gladkikh, A. et al. (2010) Cyclin D1 expression in B-cell lymphomas.
    Exp Hematol. 38 (11): 1047-57.
  16. Unruh, T.L. et al. (2005) Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
    Immunology. 116 (2): 223-32.
  17. Gladkikh, A.A. et al. (2017) Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
    Cancer Med. 6 (12): 2984-97.
Request a different product with the B Cells specificity